Schall Thomas J.

Director, President and CEO · SEC CIK 1423084
Advertisement

Buy track record

How this insider's open-market purchases have performed
75%
of buys now in profit
3 up · 1 down
Avg return since buy+58.8%
Median return+48.9%
Best trade+142.3%
Worst trade−5.0%
Buys scored4
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +31.2% 75% won · 4 trades
After 3 months +104.2% 75% won · 4 trades
After 6 months +101.1% 100% won · 3 trades
After 12 months +55.3% 50% won · 2 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Jan 15, 2026 IMRX $5 $101K +41% +10.3% +23.9% −5.0%
Jun 27, 2025 IMRX $4 $34.8K +22% +10.8% +91.2% +88.7% +24.9%
Jun 17, 2025 IMRX $2 $89.3K +999% +136.3% +343.4% +202.2% +142.3% +142.3%
Mar 22, 2024 IMRX $3 $7.4K NEW −32.5% −41.6% +12.5% −31.8% +72.9%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 4 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$232.5K
4 trades
Open-market sells
$54.11M
46 trades
Net flow
−$53.88M
Net selling
Total filings
98
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
IMRX
Buy Schall Thomas J. · Director · Open-market purchase · filed Jan 20, 2026 ΔOwn +41%

Schall Thomas J., IMRX's Director, spent $101K of their own money on 21,645 shares at $5, growing their stake 41%.

+$101K
21,645 sh @ $5
IMRX
Buy Schall Thomas J. · Director · Open-market purchase · filed Jun 30, 2025 ΔOwn +22%

Schall Thomas J., IMRX's Director, spent $34.8K of their own money on 9,500 shares at $4, growing their stake 22%.

+$34.8K
9,500 sh @ $4
IMRX
Buy Schall Thomas J. · Director · Open-market purchase · filed Jun 18, 2025 ΔOwn +999%

Schall Thomas J., IMRX's Director, spent $89.3K of their own money on 40,485 shares at $2, growing their stake 1396%.

+$89.3K
40,485 sh @ $2
IMRX
Buy Schall Thomas J. · Director · Open-market purchase · filed Mar 25, 2024 ΔOwn NEW

Schall Thomas J., IMRX's Director, spent $7.4K of their own money on 2,900 shares at $3, opening a brand-new position.

+$7.4K
2,900 sh @ $3
CCXI
Disposition to issuer Schall Thomas J. · Director, President and CEO · Disposition to issuer · filed Oct 24, 2022 ΔOwn −100%
−$0
2.39M sh
Advertisement
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed Aug 8, 2022 ΔOwn −5.2%

Schall Thomas J. sold $6.53M of CCXI, trimming their stake 5%.

−$6.53M
130,000 sh @ $50
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed Dec 16, 2020 ΔOwn −0.8%

Schall Thomas J. sold $1.15M of CCXI, trimming their stake 1%.

−$1.15M
17,619 sh @ $65
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed Dec 16, 2020 ΔOwn −0.5%

Schall Thomas J. sold $725.2K of CCXI.

−$725.2K
11,153 sh @ $65
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed Jun 16, 2020 ΔOwn −0.1%

Schall Thomas J. sold $130.1K of CCXI.

−$130.1K
2,000 sh @ $65
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed Jun 16, 2020 ΔOwn −3.8%

Schall Thomas J. sold $5.78M of CCXI, trimming their stake 4%.

−$5.78M
88,753 sh @ $65
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed May 12, 2020 ΔOwn −1.6%

Schall Thomas J. sold $2.07M of CCXI, trimming their stake 2%.

−$2.07M
35,865 sh @ $58
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed May 12, 2020 ΔOwn −2.3%

Schall Thomas J. sold $3.02M of CCXI, trimming their stake 2%.

−$3.02M
54,579 sh @ $55
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed May 12, 2020 ΔOwn −0.7%

Schall Thomas J. sold $899.9K of CCXI, trimming their stake 1%.

−$899.9K
16,029 sh @ $56
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed May 12, 2020 ΔOwn −0.2%

Schall Thomas J. sold $231.1K of CCXI.

−$231.1K
4,201 sh @ $55
CCXI
Sell Schall Thomas J. · Director, President and CEO · Open-market sale · filed May 7, 2020 ΔOwn −0.4%

Schall Thomas J. sold $486.9K of CCXI.

−$486.9K
8,851 sh @ $55

Frequently asked questions

How is Schall Thomas J.'s win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Schall Thomas J.'s SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.